Peer-reviewed veterinary case report
Antioxidant supplements to help treat canine leishmaniasis
By de Sousa Gonçalves, Rafaela et al.·Published in Veterinary parasitology·2021·Teaching Hospital of Veterinary Medicine, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Nutritional adjuvants with antioxidant properties in the treatment of canine leishmaniasis.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with canine leishmaniasis (a disease caused by a parasite) received a combination of anti-parasitic medications and nutritional supplements, including omega-3 fatty acids and B vitamins, to see if this would help them recover better. The dogs that started the nutritional supplements before the anti-parasitic treatment showed better control of inflammation and improved blood protein levels compared to those who started the supplements later. This suggests that giving these nutritional supplements early on can be beneficial for dogs undergoing treatment for this condition.
People also search for: dog leishmaniasis treatment · omega-3 for dogs with leishmaniasis · canine leishmaniasis recovery time
Abstract
Clinical improvement of dogs treated for canine leishmaniasis (CanL) requires reducing Leishmania infantum loads, which depend on intracellular oxidant compounds to destroy the parasite. However, oxidative species' excess and antioxidants consumption can culminate in oxidative stress, resulting in increased, widespread inflammation. We aimed to evaluate if early or late addition of nutritional adjuvants (NAs) - omega-3 polyunsaturated fatty acids and B vitamins - to anti-Leishmania drugs (ALDs) in the treatment of CanL would be clinically beneficial. For that, serum biomarkers including oxidative stress parameters were analyzed during 12 months in dogs allocated to two treatment groups: (G1) NAs administered from 30 days prior to the beginning of ALDs; and (G2) NAs administered from 61 days after the beginning of ALDs. Both G1 and G2 continued to receive NAs until the 12th month. The ALDs administered were metronidazole associated with ketoconazole (40 days), followed by allopurinol from day 41 until the 12th month. G1 exhibited superior inflammation control, with reduced globulins (p = 0.025), specific anti-Leishmania immunoglobulins (p = 0.016), total protein (p = 0.031), and an increased serum albumin/globulin ratio (p = 0.033), compared to G2. The early use of NAs associated with ALDs is clinically beneficial in treating dogs with CanL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34271314/